PBYI
Puma Biotechnology, Inc.
9.80$
+2.4%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +47.4% | +5.4% | -34.5% | +56.5% | -9.3% | +4.0% | -7.2% | -2.0% | +3.8% | -7.5% | +1.4% | |
| – | +49.7% | +5.8% | -55.0% | +90.8% | -18.1% | -12.1% | -4.2% | -4.1% | +16.3% | -5.5% | +10.2% | |
| – | -17.9% | +515.5% | -58.0% | +32.7% | -44.6% | +42.1% | -26.0% | +20.7% | +11.0% | -18.2% | -57.2% | |
| – | -17.9% | +515.5% | -58.0% | +32.7% | +3.0% | -16.4% | -12.1% | -1.3% | +18.3% | +5.2% | -3.4% | |
| – | – | – | – | +127.0% | +31.7% | -11.6% | +27.3% | +30.0% | +14.7% | -34.0% | +67.6% | |
| – | -100.0% | – | – | +29.4% | +20.8% | +9.0% | +105.8% | -36.3% | +56.4% | +23.2% | -36.8% | |
| – | +10.5% | +116.2% | -13.3% | -11.3% | -16.6% | -24.9% | +535.8% | -92.7% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -8.2% | -8.9% | +83.2% | -10.8% | +6.8% | -13.8% | -16.0% | -19.0% | |
| – | -26.0% | +27.0% | +161.2% | +100.3% | -3.3% | +15.1% | -8.5% | -12.5% | -11.7% | -31.6% | -29.1% | |
| – | -27.0% | +15.5% | +55.7% | +15.0% | +35.3% | +25.8% | -4.1% | -29.3% | +28.3% | -3.3% | -15.5% | |
| – | – | – | – | – | – | +562.3% | -79.4% | +15.8% | +837.1% | +31.1% | -53.1% | |
| – | +18.7% | +12.5% | +38.2% | -25.3% | -7.3% | -37.0% | -7.5% | -42.4% | +7.0% | -20.0% | -8.2% | |
| – | – | – | – | +213.3% | -37.5% | -11.5% | +15.6% | +1.3% | -33.2% | -66.9% | – | |
| – | +76.1% | +1.8% | -74.6% | -35.6% | -49.1% | -134.1% | – | – | +147.3% | +72.4% | +41.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +7.0% | +3.6% | +11.6% | +2.1% | +2.2% | +2.1% | +2.7% | +10.6% | +5.8% | +3.3% | +3.2% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.